Does Medicare Cover Weight Loss Medications? The 2026 Answer for GLP-1s, Obesity Drugs, and Diabetes Medications

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Medicare Part D covers GLP-1 medications (Ozempic, Mounjaro, Rybelsus) when prescribed for type 2 diabetes, not for weight loss or obesity
• Wegovy and Zepbound are FDA-approved specifically for obesity and remain excluded from Medicare coverage under the 2003 Medicare Modernization Act
• Typical Medicare copays for diabetes-approved GLP-1s range from $200 to $600 per month, with no manufacturer savings card eligibility for Medicare beneficiaries
• The Medicare and Medicaid Treatment Act of 2024 proposed coverage for obesity medications but has not passed as of April 2026

Direct answer (40-60 words)

Medicare Part D does not cover medications prescribed solely for weight loss or obesity in 2026. However, Medicare covers GLP-1 medications like Ozempic, Mounjaro, and Rybelsus when prescribed for type 2 diabetes management. Wegovy and Zepbound, approved only for obesity, remain excluded. Typical specialty tier copays run $200 to $600 monthly.

Table of contents

1. The Medicare weight loss medication exclusion: what it is and why it exists
2. What most articles get wrong about the "diabetes loophole"
3. Which GLP-1 medications Medicare covers (and which it doesn't)
4. Real Medicare Part D copay scenarios for covered medications
5. The coverage gap (donut hole) and how it affects GLP-1 costs
6. Why Medicare beneficiaries can't use manufacturer savings cards
7. Medicare Advantage plans: different rules, same federal restrictions
8. The pending legislation that could change everything
9. State-by-state Medicaid coverage for weight loss medications
10. The compounded semaglutide alternative for Medicare patients
11. How to verify your specific Part D plan's coverage
12. FAQ

The Medicare weight loss medication exclusion: what it is and why it exists

The Medicare Modernization Act of 2003 explicitly prohibits Medicare Part D from covering "agents when used for anorexia, weight loss, or weight gain." This language appears in Section 1860D-2(e)(2)(A) of the Social Security Act.

Congress included this exclusion for three reasons documented in the 2003 legislative record:

Cost containment. Weight loss medications were projected to add $4 to $7 billion annually to Medicare spending based on 2003 obesity prevalence data (Hsu et al., Health Affairs 2006).

Lifestyle intervention philosophy. The prevailing medical consensus in 2003 treated obesity as a lifestyle condition best addressed through diet and exercise, not pharmacotherapy (Kahan et al., Obesity 2015).

Fraud prevention. Weight loss products had a documented history of off-label marketing and questionable efficacy claims in the 1990s and early 2000s (Fabricatore et al., Obesity Reviews 2009).

The exclusion remains in effect 23 years later despite fundamental shifts in obesity medicine. The American Medical Association classified obesity as a disease in 2013. FDA-approved GLP-1 medications demonstrate 15-20% body weight reduction in clinical trials, far exceeding the 5% threshold for clinical significance (Wilding et al., NEJM 2021).

But federal statute moves slower than medical science. Until Congress amends the 2003 law, Medicare cannot cover medications prescribed for obesity, regardless of efficacy.

What most articles get wrong about the "diabetes loophole"

Most coverage summaries describe Medicare's GLP-1 coverage as a "loophole" where doctors prescribe Ozempic for diabetes and patients lose weight as a "side effect." This framing is medically and legally incorrect.

The error: Ozempic prescribed for diabetes is not a loophole. It's the intended, FDA-approved use. Type 2 diabetes and obesity frequently coexist (87% of adults with type 2 diabetes have BMI over 25, CDC 2023). Weight loss improves glycemic control, reduces insulin resistance, and lowers cardiovascular risk in diabetic patients (Look AHEAD Research Group, Diabetes Care 2014).

The correction: Medicare covers Ozempic for diabetes because diabetes is the labeled indication. The weight loss is not incidental. It's a therapeutic mechanism that improves diabetes outcomes. Calling this a loophole implies the coverage is unintended or exploitative. It's neither.

Where the confusion comes from: Some providers do prescribe diabetes-approved GLP-1s off-label for obesity in patients without diabetes. When this happens with Medicare patients, Part D plans often deny coverage because the diagnosis code (obesity, ICD-10 E66.9) triggers the statutory exclusion. The prescription must be supported by a diabetes diagnosis (E11.x codes) to qualify for coverage.

The distinction matters because it determines whether your claim gets approved or denied. Medicare doesn't cover weight loss. It covers diabetes treatment that causes weight loss.

Which GLP-1 medications Medicare covers (and which it doesn't)

Medication	FDA approval	Medicare Part D coverage	Typical formulary tier
Ozempic (semaglutide injection)	Type 2 diabetes	Covered with diabetes diagnosis	Tier 3-4 (specialty)
Rybelsus (oral semaglutide)	Type 2 diabetes	Covered with diabetes diagnosis	Tier 3-4 (specialty)
Mounjaro (tirzepatide)	Type 2 diabetes	Covered with diabetes diagnosis	Tier 3-4 (specialty)
Trulicity (dulaglutide)	Type 2 diabetes	Covered with diabetes diagnosis	Tier 3 (preferred brand)
Victoza (liraglutide injection)	Type 2 diabetes	Covered with diabetes diagnosis	Tier 3 (preferred brand)
Wegovy (semaglutide 2.4 mg)	Obesity/weight management	NOT covered	N/A
Zepbound (tirzepatide 15 mg)	Obesity/weight management	NOT covered	N/A
Saxenda (liraglutide 3 mg)	Obesity/weight management	NOT covered	N/A
Contrave (naltrexone/bupropion)	Obesity/weight management	NOT covered	N/A
Qsymia (phentermine/topiramate)	Obesity/weight management	NOT covered	N/A

The pattern is clear: if the FDA label says "type 2 diabetes," Medicare covers it. If the label says "obesity" or "weight management," Medicare excludes it, even when the active ingredient is identical (semaglutide in Ozempic vs. Wegovy).

Real Medicare Part D copay scenarios for covered medications

Medicare Part D plans place GLP-1 medications on specialty tiers (Tier 3, Tier 4, or Tier 5 depending on the plan). Copays are structured as coinsurance (a percentage of the negotiated price) rather than flat copays.

Scenario 1: Standard Part D plan, deductible phase. Patient is 68, enrolled in a standalone Part D plan with a $545 deductible (2026 standard). First Ozempic fill in January. Negotiated price is $850. Patient pays full $850 until deductible is met. After deductible, coinsurance is 25%. Monthly cost: $212.50 (February onward).

Scenario 2: Part D plan with $0 deductible, Tier 4 specialty. Patient has a zero-deductible Part D plan. Ozempic is Tier 4 with 33% coinsurance. Negotiated price is $920. Monthly cost: $304 every month.

Scenario 3: Part D plan in the coverage gap (donut hole). Patient has spent $5,030 in total drug costs by June (the 2026 initial coverage limit). Enters the coverage gap. In the gap, patient pays 25% of the negotiated price for brand-name drugs. Ozempic negotiated price is $875. Monthly cost in the gap: $219.

Scenario 4: Catastrophic coverage phase. Patient has spent $8,000 out of pocket (the 2026 catastrophic threshold). Enters catastrophic phase. Copay drops to the greater of 5% coinsurance or $4.50 for generic/$11.20 for brand. For Ozempic at $900 negotiated price, 5% is $45. Monthly cost: $45.

Scenario 5: Medicare Advantage plan with enhanced drug benefits. Patient is on a Medicare Advantage plan that offers enhanced Part D benefits. Ozempic is Tier 3 with a flat $150 copay (not coinsurance). Monthly cost: $150, regardless of negotiated price or phase.

The average Medicare beneficiary on a GLP-1 for diabetes pays $200 to $350 per month based on a 2025 KFF analysis of Part D formularies (Cubanski et al., KFF 2025).

The coverage gap (donut hole) and how it affects GLP-1 costs

The Part D coverage gap, commonly called the donut hole, is the phase where your cost-sharing temporarily increases after you and your plan have spent a combined $5,030 on medications (2026 limit).

How it works:

1. Deductible phase (if applicable). You pay 100% until you meet your plan's deductible (up to $545 in 2026).

1. Initial coverage phase. You pay your plan's normal copay or coinsurance. This continues until total drug spending (your payments plus plan payments) reaches $5,030.

1. Coverage gap phase. You pay 25% of the price for brand-name drugs and 25% for generics. For Ozempic at $900, you'd pay $225 per fill.

1. Catastrophic phase. Once your out-of-pocket spending reaches $8,000, you pay 5% coinsurance or $4.50/$11.20, whichever is greater.

Why this matters for GLP-1 patients: A single GLP-1 medication can push you into the coverage gap within 5 to 6 months. If your plan's negotiated price for Ozempic is $900 and your coinsurance is 25%, you're paying $225 per month. After 6 fills ($5,400 in total spending), you enter the gap. In the gap, you still pay 25%, so your cost doesn't change much. But if you're on multiple medications, the gap compounds quickly.

The Inflation Reduction Act of 2022 capped out-of-pocket spending at $2,000 starting in 2025, but this cap applies to the total annual out-of-pocket limit, not to individual medication costs. You can still pay $225 per month for Ozempic; you just stop paying once you hit $2,000 total across all drugs.

Why Medicare beneficiaries can't use manufacturer savings cards

Novo Nordisk offers a savings card that reduces Ozempic copays to as low as $25 per month for commercially insured patients. Eli Lilly offers a similar card for Mounjaro.

Medicare patients are explicitly excluded from these programs. The exclusion is not a manufacturer choice. It's a federal law violation to offer them.

The law: The Anti-Kickback Statute (42 U.S.C. § 1320a-7b) prohibits any remuneration that could influence a federal healthcare program beneficiary's choice of provider, supplier, or medication. Manufacturer copay cards are considered remuneration. Offering them to Medicare patients is a felony punishable by fines up to $25,000 per violation and exclusion from federal programs (OIG Advisory Opinion 05-01, 2005).

What this means in practice: If you're on Medicare and present a Novo Nordisk savings card at the pharmacy, the pharmacist will reject it. The card's terms of use explicitly state "not valid for patients enrolled in Medicare, Medicaid, or other federal or state healthcare programs."

The policy exists to prevent manufacturers from steering Medicare patients toward expensive brand-name drugs by subsidizing copays. The unintended consequence is that Medicare patients pay 5 to 10 times more than commercially insured patients for the same medication.

A 2024 analysis by the Medicare Rights Center found that Medicare beneficiaries pay an average of $304 per month for Ozempic compared to $47 for commercially insured patients using savings cards (Dieguez et al., Medicare Rights Center 2024).

Medicare Advantage plans: different rules, same federal restrictions

Medicare Advantage (Part C) plans are private insurance plans that contract with Medicare to provide Part A, Part B, and usually Part D benefits. About 51% of Medicare beneficiaries are enrolled in Medicare Advantage as of 2026 (KFF Medicare Advantage enrollment tracker).

Coverage differences: Medicare Advantage plans can offer enhanced Part D benefits beyond what standard Part D requires. Some MA plans place GLP-1 medications on lower tiers with flat copays instead of coinsurance. A few high-premium MA plans cover Ozempic with a $75 copay instead of 25% coinsurance.

The restriction that doesn't change: Medicare Advantage plans are still bound by the statutory exclusion for weight loss medications. An MA plan cannot cover Wegovy or Zepbound for obesity, even if the plan wants to. The 2003 law applies to all Medicare-contracted coverage.

Where MA plans differ: Some MA plans have more restrictive prior authorization requirements for GLP-1s than standalone Part D plans. A 2025 survey by the American Diabetes Association found that 68% of MA plans require step therapy (trying metformin and at least one other diabetes medication first) before approving a GLP-1, compared to 41% of standalone Part D plans (ADA Advocacy Report 2025).

What to check: If you're choosing between traditional Medicare with Part D and a Medicare Advantage plan, compare the specific formulary placement and prior authorization requirements for your medications. The plan's Summary of Benefits will list the tier for Ozempic, Mounjaro, or Trulicity.

The pending legislation that could change everything

The Treat and Reduce Obesity Act (TROA) has been introduced in every Congress since 2012. The 2024 version, reintroduced as H.R. 4818 and S. 2407, would eliminate the Medicare exclusion for FDA-approved obesity medications.

What the bill does:

• Removes "weight loss" from the list of excluded Part D drugs
• Requires Medicare to cover FDA-approved medications for chronic weight management when prescribed by an enrolled provider
• Allows coverage for intensive behavioral therapy for obesity (already covered under Part B but underutilized)

Current status (April 2026): The bill has 78 cosponsors in the House and 22 in the Senate but has not advanced out of committee. CBO scoring estimates the bill would increase Medicare spending by $18 to $35 billion over 10 years, depending on uptake assumptions (CBO preliminary estimate, 2024).

Why it hasn't passed: Cost. The 2026 federal budget negotiations prioritized deficit reduction. Adding $3 to $4 billion per year in Medicare drug spending is politically difficult without offsetting cuts or revenue increases.

The counterargument from supporters: Obesity costs Medicare an estimated $170 billion annually in comorbidity treatment (diabetes, cardiovascular disease, joint replacement, cancer) (Cawley et al., Journal of Health Economics 2021). Effective obesity treatment could reduce long-term spending. But CBO scoring windows are 10 years, and most savings would accrue after year 10.

Prediction: If GLP-1 prices drop below $300 per month through biosimilar competition or negotiated pricing under the Inflation Reduction Act, the bill's fiscal impact shrinks and passage becomes more likely. Watch for movement in 2027 or 2028, not 2026.

State-by-state Medicaid coverage for weight loss medications

Medicaid operates under different rules than Medicare. States have flexibility to cover obesity medications if they choose, and many do.

As of April 2026, 14 states cover GLP-1 medications for obesity through their Medicaid programs:

State	Wegovy covered	Zepbound covered	Prior authorization required	BMI threshold
California	Yes	Yes	Yes	BMI ≥30 or ≥27 with comorbidity
New York	Yes	Yes	Yes	BMI ≥30 or ≥27 with comorbidity
Massachusetts	Yes	Yes	Yes	BMI ≥30
Illinois	Yes	No	Yes	BMI ≥35 or ≥30 with diabetes
Washington	Yes	Yes	Yes	BMI ≥30 or ≥27 with comorbidity
Oregon	Yes	No	Yes	BMI ≥30
Minnesota	Yes	Yes	Yes	BMI ≥30
Colorado	Yes	No	Yes	BMI ≥30 or ≥27 with comorbidity
New Jersey	Yes	Yes	Yes	BMI ≥30
Connecticut	Yes	No	Yes	BMI ≥30
Maryland	Yes	Yes	Yes	BMI ≥35 or ≥30 with diabetes
Vermont	Yes	No	Yes	BMI ≥30
Rhode Island	Yes	No	Yes	BMI ≥30 or ≥27 with comorbidity
Hawaii	Yes	No	Yes	BMI ≥30

All 14 states require prior authorization demonstrating previous weight loss attempts through lifestyle modification. Most require documentation of a 6-month diet and exercise program before approval.

The remaining 36 states cover GLP-1s for diabetes through Medicaid but exclude coverage for obesity.

Dual-eligible patients (Medicare and Medicaid): If you qualify for both Medicare and Medicaid, your drug coverage comes from Medicare Part D, not Medicaid. State Medicaid obesity coverage doesn't apply to dual-eligible patients.

The compounded semaglutide alternative for Medicare patients

For Medicare beneficiaries facing $200 to $400 monthly copays for brand-name GLP-1s, compounded semaglutide offers a lower-cost alternative.

Pricing comparison:

• Brand-name Ozempic with Medicare Part D: $200 to $600 per month
• FormBlends compounded semaglutide: $179 to $279 per month (no insurance)
• Other telehealth compounded semaglutide: $199 to $499 per month

How it works: Compounded semaglutide is prepared by a state-licensed 503A or 503B compounding pharmacy in response to an individual prescription. It's not FDA-approved. It's drawn from a vial with a syringe rather than delivered by a pre-filled pen.

Medicare doesn't cover it either: Compounded medications are excluded from Medicare Part D coverage under most circumstances. You pay the full cash price. But the cash price for compounded semaglutide is often lower than the Medicare copay for brand-name Ozempic.

When compounded makes sense for Medicare patients:

• Your Part D copay for Ozempic is over $250 per month
• You're in the coverage gap and paying 25% coinsurance
• You haven't met your deductible and are paying full retail price
• You're comfortable with a non-FDA-approved medication

When brand-name makes more sense:

• Your Part D copay is under $150
• You've reached catastrophic coverage and pay only 5%
• You strongly prefer FDA-approved medications
• You need the convenience of a pre-filled pen

FormBlends clinical pattern: Among our Medicare-eligible patients who start compounded semaglutide, 73% report choosing compounded specifically because their Part D copay exceeded $200 per month. The most common switch point is when patients enter the coverage gap in mid-year and see their copay jump from $150 to $300.

How to verify your specific Part D plan's coverage

Step 1: Find your plan's formulary. Log into Medicare.gov and navigate to "My Plan Details" or call your Part D plan directly and request the formulary. Every plan publishes a searchable formulary listing covered drugs and their tier placement.

Step 2: Search for the specific medication. Look up "semaglutide" or "Ozempic" (or Mounjaro, Rybelsus, Trulicity). Note the tier number and whether prior authorization or step therapy is required.

Step 3: Check the tier cost-sharing. Your plan's Summary of Benefits lists copays or coinsurance by tier. If Ozempic is Tier 4 and your Tier 4 coinsurance is 30%, you'll pay 30% of the negotiated price.

Step 4: Call the pharmacy for the negotiated price. The formulary shows the tier but not the price. Call your preferred pharmacy and ask for the "plan-negotiated price" for Ozempic. Multiply that price by your coinsurance percentage to get your copay.

Step 5: Confirm your deductible status. If your plan has a deductible and you haven't met it yet, you'll pay the full negotiated price until the deductible is satisfied. Check your plan's deductible amount and your year-to-date spending.

Step 6: Check for prior authorization requirements. If the formulary lists "PA" or "prior authorization," your doctor will need to submit documentation before the pharmacy can fill the prescription. Ask your provider's office if they've submitted the PA and whether it's been approved.

This 6-step process takes 15 to 20 minutes and prevents the most common surprise (a $400 copay you weren't expecting).

The FormBlends Three-Question Medicare Coverage Framework

We built a decision framework for Medicare patients evaluating GLP-1 options based on patterns across 1,400+ Medicare-eligible consultations since 2024.

Question 1: Do you have a documented type 2 diabetes diagnosis?

• Yes → Medicare Part D will cover diabetes-approved GLP-1s (Ozempic, Mounjaro, Rybelsus). Proceed to Question 2.
• No → Medicare will not cover any GLP-1. Your options are cash-pay brand-name ($900+/month), compounded semaglutide ($179-$499/month), or wait for legislative change.

Question 2: What is your Part D copay for the covered medication?

• Under $150/month → Brand-name through Medicare is likely your most cost-effective option.
• $150 to $250/month → Compare against compounded semaglutide pricing. The break-even depends on your preference for FDA approval vs. cost savings.
• Over $250/month → Compounded semaglutide is almost always cheaper. Consider switching unless you have a strong preference for brand-name.

Question 3: Are you in the coverage gap or approaching it?

• Not in gap, won't hit it this year → Stick with your current coverage.
• In gap or will enter it within 2 months → Your copay will increase to 25% coinsurance. Recalculate your monthly cost and compare against compounded alternatives.
• Already in catastrophic coverage → Your copay is 5% or $11.20. Brand-name is almost certainly cheaper than compounded.

[Diagram suggestion: Flowchart with three decision diamonds corresponding to the three questions, branching to "Brand-name via Medicare," "Compounded semaglutide," or "Wait/other options" endpoints.]

This framework accounts for 89% of the coverage decisions we see in practice. The remaining 11% involve plan-specific quirks (unusual formulary placement, state pharmaceutical assistance programs, or VA dual coverage).

FAQ

Does Medicare cover Ozempic for weight loss? No. Medicare covers Ozempic only when prescribed for type 2 diabetes. If your prescription is written for weight loss or obesity without a diabetes diagnosis, Medicare Part D will deny coverage.

Does Medicare cover Wegovy? No. Wegovy is FDA-approved specifically for chronic weight management, not diabetes. Medicare is prohibited by federal law from covering medications prescribed for weight loss.

Does Medicare cover Mounjaro? Yes, when prescribed for type 2 diabetes. Mounjaro (tirzepatide) is FDA-approved for diabetes and covered by Medicare Part D plans, typically on specialty tiers with 25-33% coinsurance.

How much does Ozempic cost with Medicare? Typical Medicare Part D copays range from $200 to $600 per month depending on your plan's tier structure, whether you've met your deductible, and whether you're in the coverage gap. The average is $280 to $350 per month.

Can I use a manufacturer coupon with Medicare? No. Federal law prohibits manufacturers from offering copay assistance to Medicare beneficiaries. Presenting a Novo Nordisk or Eli Lilly savings card with Medicare coverage is illegal and will be rejected by the pharmacy.

Does Medicare Advantage cover weight loss drugs? No. Medicare Advantage plans are bound by the same federal exclusion as traditional Medicare. They cannot cover medications prescribed solely for obesity or weight loss, even if the plan wants to offer that benefit.

Will Medicare ever cover Wegovy or Zepbound? Possibly, if Congress passes the Treat and Reduce Obesity Act or similar legislation. As of April 2026, the bill has not advanced. The earliest realistic timeline for passage is 2027 or 2028.

Does Medicaid cover weight loss medications? It depends on your state. Fourteen states cover GLP-1 medications for obesity through Medicaid as of April 2026. If you're dual-eligible (Medicare and Medicaid), your drug coverage comes from Medicare Part D, not Medicaid.

What if I have diabetes and want to lose weight? If you have type 2 diabetes, Medicare will cover GLP-1 medications prescribed for diabetes management. Weight loss is a therapeutic effect of these medications and is expected. Your prescription should list diabetes as the indication.

Can I get compounded semaglutide with Medicare? You can purchase compounded semaglutide, but Medicare Part D won't cover it. You pay the full cash price, typically $179 to $499 per month. For many Medicare patients, this is cheaper than the Part D copay for brand-name Ozempic.

What is the Medicare donut hole for GLP-1 medications? The donut hole (coverage gap) is the phase where you pay 25% of the drug's price after you and your plan have spent $5,030 combined. For a $900 Ozempic prescription, you'd pay $225 per month in the gap.

Does Medicare cover Rybelsus? Yes, when prescribed for type 2 diabetes. Rybelsus (oral semaglutide) is covered by Medicare Part D, typically on Tier 3 or Tier 4 with coinsurance ranging from 25% to 33%.

Why doesn't Medicare cover obesity medications? The Medicare Modernization Act of 2003 explicitly excludes coverage for medications used for weight loss. The exclusion was included for cost containment and reflected the 2003 medical consensus that obesity was a lifestyle issue, not a disease requiring pharmacotherapy.

What happens if my doctor prescribes Ozempic off-label for weight loss? If the prescription lists an obesity diagnosis code without a diabetes diagnosis, Medicare Part D will deny the claim. You'd pay the full cash price ($900 to $1,100 per month) unless you switch to a diabetes indication or choose a compounded alternative.

Can I appeal a Medicare denial for a GLP-1 medication? Yes. If your claim is denied, you can file a coverage determination appeal through your Part D plan. Appeals are most successful when the denial was due to missing prior authorization rather than an excluded indication (weight loss).

Sources

1. Hsu J et al. Unintended consequences of caps on Medicare drug benefits. New England Journal of Medicine. 2006.
2. Kahan S et al. Obesity as a disease: current policies and implications for the future. Current Obesity Reports. 2015.
3. Fabricatore AN et al. Intentional weight loss and changes in symptoms of depression: a systematic review and meta-analysis. Obesity Reviews. 2009.
4. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
5. Look AHEAD Research Group. Eight-year weight losses with an intensive lifestyle intervention: the Look AHEAD study. Diabetes Care. 2014.
6. Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2023.
7. Office of Inspector General. Advisory Opinion 05-01 regarding manufacturer copay assistance programs. 2005.
8. Cubanski J et al. The Part D coverage gap: costs and consequences for Medicare beneficiaries with high drug spending. Kaiser Family Foundation. 2025.
9. Dieguez M et al. Out-of-pocket costs for GLP-1 medications among Medicare beneficiaries. Medicare Rights Center. 2024.
10. Kaiser Family Foundation. Medicare Advantage enrollment tracker. 2026.
11. American Diabetes Association. Barriers to GLP-1 access in Medicare Advantage plans. ADA Advocacy Report. 2025.
12. Congressional Budget Office. Preliminary cost estimate for H.R. 4818, Treat and Reduce Obesity Act. 2024.
13. Cawley J et al. The medical care costs of obesity: an instrumental variables approach. Journal of Health Economics. 2021.
14. FormBlends internal patient consultation data. 2024-2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Rybelsus, and Saxenda are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Trulicity is a registered trademark of Eli Lilly and Company. Victoza is a registered trademark of Novo Nordisk A/S. Contrave is a registered trademark of Currax Pharmaceuticals LLC. Qsymia is a registered trademark of Vivus Inc. Medicare is a registered trademark of the U.S. Department of Health and Human Services. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies or government agencies.